Genprex, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Genprex, Inc. is a clinical-stage gene therapy company focused on developing innovative therapies for patients with cancer and diabetes. The company’s core products include its lead candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), which is being evaluated in multiple clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Reqorsa uses the company's proprietary systemic, non-viral Oncoprex® Delivery System that encapsulates gene-expressing plasmids in lipid-based nanoparticles for intravenous administration, targeting tumor cells to express tumor suppressor proteins. Genprex also develops gene therapies for diabetes, including GPX-002, which utilizes an AAV vector to deliver Pdx1 and MafA genes to the pancreas aiming to restore insulin production by transforming alpha cells into beta-like cells. The company’s products have received FDA Fast Track Designations for their lung cancer programs, and the SCLC program has obtained Orphan Drug Designation. Recent major developments include the addition of new clinical trial sites, such as the Gabrail Cancer Center in Canton, Ohio, to support ongoing Acclaim-1 and Acclaim-3 trials of Reqorsa for lung cancer. Genprex secured a U.S. patent covering the use of Reqorsa in combination with PD-L1 antibodies for cancer treatment, with patent protection extending through 2037 and pending applications in several key international markets. The company announced in 2024 plans to launch a separate subsidiary focused exclusively on gene therapy development for type 1 and type 2 diabetes, aiming to provide a more focused approach to its oncology and diabetes programs. In 2025, Genprex completed a registered direct offering to support ongoing clinical trials and operational growth. The company continues to collaborate with leading research institutions, including the University of Michigan Rogel Cancer Center and the University of Pittsburgh, under Sponsored Research Agreements to advance its gene therapy pipeline. Founded in 2008, Genprex is headquartered in Austin, Texas, and operates primarily in the United States with ongoing expansion efforts in clinical trial sites and international patent filings. Its business segments center on oncology and diabetes gene therapies targeting large patient populations with unmet medical needs. Genprex’s strategic focus remains on advancing its pipeline through clinical development, securing intellectual property, and executing strategic financing to support innovative gene therapy solutions for cancer and diabetes patients worldwide.
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison
Genprex (GNPX) Expected to Announce Quarterly Earnings on Friday
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex to Participate at BIO Europe Spring 2026
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of
Genprex Provides Clinical Update on Diabetes Gene Therapy Program
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
Move Over, Pelosi: This Congress Member Posted 2025's Best Market Return With A 52% Gain
Genprex (NASDAQ:GNPX) Stock Price Down 3.8% – What’s Next?
Rep. Tim Moore Purchases Shares of Genprex (NASDAQ:GNPX)
Hyster-Yale (NYSE:HY) Shares Acquired Rep. Tim Moore